These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
378 related articles for article (PubMed ID: 26497654)
21. A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer. Suenaga M; Mizunuma N; Matsusaka S; Shinozaki E; Ozaka M; Ogura M; Chin K; Yamaguchi T Drug Des Devel Ther; 2015; 9():1653-62. PubMed ID: 25834402 [TBL] [Abstract][Full Text] [Related]
22. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. Cremolini C; Antoniotti C; Rossini D; Lonardi S; Loupakis F; Pietrantonio F; Bordonaro R; Latiano TP; Tamburini E; Santini D; Passardi A; Marmorino F; Grande R; Aprile G; Zaniboni A; Murgioni S; Granetto C; Buonadonna A; Moretto R; Corallo S; Cordio S; Antonuzzo L; Tomasello G; Masi G; Ronzoni M; Di Donato S; Carlomagno C; Clavarezza M; Ritorto G; Mambrini A; Roselli M; Cupini S; Mammoliti S; Fenocchio E; Corgna E; Zagonel V; Fontanini G; Ugolini C; Boni L; Falcone A; Lancet Oncol; 2020 Apr; 21(4):497-507. PubMed ID: 32164906 [TBL] [Abstract][Full Text] [Related]
23. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. Cassidy J; Tabernero J; Twelves C; Brunet R; Butts C; Conroy T; Debraud F; Figer A; Grossmann J; Sawada N; Schöffski P; Sobrero A; Van Cutsem E; Díaz-Rubio E J Clin Oncol; 2004 Jun; 22(11):2084-91. PubMed ID: 15169795 [TBL] [Abstract][Full Text] [Related]
24. Multicenter randomized phase II clinical trial of oxaliplatin reintroduction as a third- or later-line therapy for metastatic colorectal cancer-biweekly versus standard triweekly XELOX (The ORION Study). Matsuda C; Honda M; Tanaka C; Fukunaga M; Ishibashi K; Munemoto Y; Hata T; Bando H; Oshiro M; Kobayashi M; Tokunaga Y; Fujii A; Nagata N; Oba K; Mishima H Int J Clin Oncol; 2016 Jun; 21(3):566-72. PubMed ID: 26475356 [TBL] [Abstract][Full Text] [Related]
25. Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study. Jackson CG; Sharples K; Thompson PI; O'Donnell A; Robinson BA; Perez DJ; Adams J; Isaacs R; Deva S; Hinder VA; Findlay MP BMC Cancer; 2014 Oct; 14():737. PubMed ID: 25274181 [TBL] [Abstract][Full Text] [Related]
26. Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety. Luo HY; Li YH; Wang W; Wang ZQ; Yuan X; Ma D; Wang FH; Zhang DS; Lin DR; Lin YC; Jia J; Hu XH; Peng JW; Xu RH Ann Oncol; 2016 Jun; 27(6):1074-1081. PubMed ID: 26940686 [TBL] [Abstract][Full Text] [Related]
27. Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group. Schmiegel W; Reinacher-Schick A; Arnold D; Kubicka S; Freier W; Dietrich G; Geißler M; Hegewisch-Becker S; Tannapfel A; Pohl M; Hinke A; Schmoll HJ; Graeven U Ann Oncol; 2013 Jun; 24(6):1580-7. PubMed ID: 23463625 [TBL] [Abstract][Full Text] [Related]
28. Phase I/II study of bi-weekly XELIRI plus bevacizumab treatment in patients with metastatic colorectal cancer resistant to oxaliplatin-based first-line chemotherapy. Mizushima T; Fukunaga M; Sueda T; Ikeda M; Kato T; Kim HM; Kudo T; Murata K; Nishimura J; Hata T; Matsuda C; Yamamoto H; Doki Y; Mori M Cancer Chemother Pharmacol; 2017 Jul; 80(1):81-90. PubMed ID: 28510802 [TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Van Cutsem E; Rivera F; Berry S; Kretzschmar A; Michael M; DiBartolomeo M; Mazier MA; Canon JL; Georgoulias V; Peeters M; Bridgewater J; Cunningham D; Ann Oncol; 2009 Nov; 20(11):1842-7. PubMed ID: 19406901 [TBL] [Abstract][Full Text] [Related]
30. Effect of Bevacizumab in Combination With Standard Oxaliplatin-Based Regimens in Patients With Metastatic Colorectal Cancer: A Randomized Clinical Trial. Avallone A; Piccirillo MC; Nasti G; Rosati G; Carlomagno C; Di Gennaro E; Romano C; Tatangelo F; Granata V; Cassata A; Silvestro L; De Stefano A; Aloj L; Vicario V; Nappi A; Leone A; Bilancia D; Arenare L; Petrillo A; Lastoria S; Gallo C; Botti G; Delrio P; Izzo F; Perrone F; Budillon A JAMA Netw Open; 2021 Jul; 4(7):e2118475. PubMed ID: 34309665 [TBL] [Abstract][Full Text] [Related]
31. A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients. Kim Y; Kim TW; Han SW; Ahn JB; Kim ST; Lee J; Park JO; Park YS; Lim HY; Kang WK Cancer Res Treat; 2019 Jul; 51(3):1128-1134. PubMed ID: 30477287 [TBL] [Abstract][Full Text] [Related]
32. Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: phase III 'Stop and Go' study results--a Turkish Oncology Group Trial. Yalcin S; Uslu R; Dane F; Yilmaz U; Zengin N; Buyukunal E; Buyukberber S; Camci C; Sencan O; Kilickap S; Ozdener F; Cevik D Oncology; 2013; 85(6):328-35. PubMed ID: 24247559 [TBL] [Abstract][Full Text] [Related]
33. Phase II study of bevacizumab, capecitabine, and oxaliplatin followed by bevacizumab plus erlotinib as first-line therapy in metastatic colorectal cancer. Muñoz A; Pericay C; García-Girón C; Alonso V; Dueñas R; Cirera L; Rivera F; Falcó E; Bustos IA; Salud A Oncol Res; 2013; 21(4):181-91. PubMed ID: 24762224 [TBL] [Abstract][Full Text] [Related]
34. Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer. Bazarbashi S; Aljubran A; Alzahrani A; Mohieldin A; Soudy H; Shoukri M Cancer Med; 2015 Oct; 4(10):1505-13. PubMed ID: 26207614 [TBL] [Abstract][Full Text] [Related]
35. Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study. Di Bartolomeo M; Ciarlo A; Bertolini A; Barni S; Verusio C; Aitini E; Pietrantonio F; Iacovelli R; Dotti KF; Maggi C; Perrone F; Bajetta E Eur J Cancer; 2015 Mar; 51(4):473-481. PubMed ID: 25637137 [TBL] [Abstract][Full Text] [Related]
36. Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205. Hoehler T; von Wichert G; Schimanski C; Kanzler S; Moehler MH; Hinke A; Seufferlein T; Siebler J; Hochhaus A; Arnold D; Hallek M; Hofheinz R; Hacker UT Br J Cancer; 2013 Sep; 109(6):1408-13. PubMed ID: 23963139 [TBL] [Abstract][Full Text] [Related]
37. Multicenter phase II study of biweekly CAPIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study). Suzuki N; Hazama S; Nagasaka T; Tanioka H; Iwamoto Y; Negoro Y; Yamauchi M; Kobayashi M; Okuda H; Fujishima N; Nishimura T; Yamanaka N; Toyota K; Mori Y; Nakagami Y; Shimokawa M; Nagano H; Okajima M Int J Clin Oncol; 2019 Oct; 24(10):1223-1230. PubMed ID: 31144145 [TBL] [Abstract][Full Text] [Related]
38. Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial. Mettu NB; Ou FS; Zemla TJ; Halfdanarson TR; Lenz HJ; Breakstone RA; Boland PM; Crysler OV; Wu C; Nixon AB; Bolch E; Niedzwiecki D; Elsing A; Hurwitz HI; Fakih MG; Bekaii-Saab T JAMA Netw Open; 2022 Feb; 5(2):e2149040. PubMed ID: 35179586 [TBL] [Abstract][Full Text] [Related]
39. Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study. Bennouna J; Borg C; Delord JP; Husseini F; Trillet-Lenoir V; Faroux R; François E; Ychou M; Goldwasser F; Bouché O; Senellart H; Kraemer S; Douillard JY Clin Colorectal Cancer; 2012 Mar; 11(1):38-44. PubMed ID: 21803002 [TBL] [Abstract][Full Text] [Related]
40. Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis. Buchler T; Pavlik T; Melichar B; Bortlicek Z; Usiakova Z; Dusek L; Kiss I; Kohoutek M; Benesova V; Vyzula R; Abrahamova J; Obermannova R BMC Cancer; 2014 May; 14():323. PubMed ID: 24884897 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]